Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data.

CONCLUSIONS: PFS in our non-trial population was significantly shorter than in the SELECT trial population. In the interpretation of results, differences in the real life population and the SELECT study population regarding patient characteristics should be taken into account.
PMID: 31751307 [PubMed - as supplied by publisher]

Source: European Journal of Endocrinology - October 31, 2019 Category: Endocrinology Authors: Aydemirli MD, Kapiteijn E, Ferrier KRM, Ottevanger N, Links TP, van der Horst-Schrivers ANA, Broekman KE, Groenwold RHH, Zwaveling J Tags: Eur J Endocrinol Source Type: research